About: Sibutramine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sibutramine Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines. Sibutramine is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. (en)
http://linked.open...generalReferences	# Sharma B, Henderson DC: Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008 Aug;9(12):2161-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18671470 # Tziomalos K, Krassas GE, Tzotzas T: The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19475780 # Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC: Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord. 1998 Aug;22 Suppl 1:S18-28; discussion S29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9758240 # Stock MJ: Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord. 1997 Mar;21 Suppl 1:S25-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9130038 (en)
http://linked.open...gy/drugbank/group	approved (en) illicit (en) withdrawn (en) investigational (en)
http://linked.open...drugbank/halfLife	1.1 hours (en)
http://linked.open...ugbank/indication	For the treatment of obesity. (en)
sameAs	Sibutramine
Title	Sibutramine (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/chemspider/5021 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/drugbank/DB01105 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/guide-to-pharmacology/2586 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/iuphar/2586 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/kegg-compound/C07247 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/kegg-drug/D08513 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/national-drug-code-directory/0074-2456-12 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/pharmgkb/PA451344 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/pubchem-compound/5210 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/pubchem-substance/46507740 http://linked.opendata.cz/resource/drugbank/drug/DB01105/identifier/wikipedia/Sibutramine
http://linked.open...mechanismOfAction	Sibutramine produces its therapeutic effects by inhibition of norepinephrine (NE), serotonin (5-hydroxytryptamine, 5-HT), and to a lesser extent, dopamine reuptake at the neuronal synapse. By inhibiting the reuptake of these neurotransmitters, sibutramine promotes a sense of satiety and decrease in appetite, thereby reducing food intake. Data from animal studies also suggest that sibutramine may also increase energy expenditure through thermogenic effects in both the basal and fed states, but this has not been confirmed in humans. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. (en)
http://linked.open...drugbank/packager	Abbott Laboratories Ltd. Apotheca Inc. A-S Medication Solutions LLC Orion Corporation Bryant Ranch Prepack Dispensing Solutions PD-Rx Pharmaceuticals Inc. Organon usa inc
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/5436272
http://linked.open...outeOfElimination	Sibutramine is metabolized in the liver principally by the cytochrome P450 (3A4) isoenzyme, to desmethyl metabolites, M1 and M2. These active metabolites are further metabolized by hydroxylation and conjugation to pharmacologically inactive metabolites, M5 and M6. Approximately 85% (range 68-95%) of a single orally administered radiolabeled dose was excreted in urine and feces over a 15-day collection period with the majority of the dose (77%) excreted in the urine. The primary route of excretion for M1 and M2 is hepatic metabolism and for M5 and M6 is renal excretion. (en)
http://linked.open.../drugbank/synonym	Butramin (en) Sibutramina (en) Sibutraminum (en)
http://linked.open...drugbank/toxicity	Side effects include dry mouth, anorexia, insomnia, constipation and headache. (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/28-20-92
http://linked.open...nk/proteinBinding	97% (to human plasma proteins) (en)
http://linked.open...ynthesisReference	Chris Senanayake, "Methods of preparing didesmethylsibutramine and other sibutramine derivatives." U.S. Patent US20020183554, issued December 05, 2002. (en)
foaf:page	http://www.drugs.com/cdi/sibutramine.html http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mer1254.shtml http://www.rxlist.com/cgi/generic/sibutramine.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4038-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B403E-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B403D-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B403A-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B403B-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B403C-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B4036-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B404D-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4034-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4037-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B404F-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B4035-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Sibutramine
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4044-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4045-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B403F-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4040-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4042-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4041-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4043-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Rapid absorption following oral administration. Absolute bioavailability is not known, but at least 77% of a single oral dose of sibutramine is absorbed. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	106650-56-0 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* Oral cl=1750 L/h [oral administration] (en)
http://linked.open...gbank/containedIn	Doxycycline Monohydrate 150 mg tablet Adoxa pak 1-100 mg tablet Ak-dilate 10% eye drops
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B4049-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B404B-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B404C-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B404E-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B4048-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B4047-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B404A-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4039-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B4046-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software